Skip to main content

Advertisement

SpringerLink
Log in

The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Overactive bladder syndrome continues to be a significant burden for the general population. Current first-line medical therapy often includes antimuscarinic medications designed for overactive bladder. Poor efficacy and significant side effects of these antimuscarinic medications have left patients and physicians looking for alternative treatments. There is increasing evidence that intradetrusor injection of botulinum toxin A can effectively treat these patients. We present a current and extensive review of the literature covering the use of botulinum toxin A in patients with overactive bladder with or without idiopathic detrusor overactivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178.

    Article  PubMed  Google Scholar 

  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327–336.

    CAS  PubMed  Google Scholar 

  3. Ganz ML, Smalarz AM, Krupski TL, et al.: Economic costs of overactive bladder in the United States. Urology 2010, 75:526–532, 532.e1–532.e18.

    Article  PubMed  Google Scholar 

  4. • Chapple C, De Ridder D: The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? BJU Int 2009, 104:1188–1190. This article discusses the roles of various treatment options for overactive bladder.

    Article  PubMed  Google Scholar 

  5. • Chapple CR, Khullar V, Gabriel Z, et al.: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543–562. This article is an extensive meta-analysis on the efficacy of current antimuscarinics available to treat overactive bladder.

    Article  CAS  PubMed  Google Scholar 

  6. Novara G: Botulinum neurotoxin type A: the poison that can treat the sick. Eur Urol 2009, 55:560–562.

    Article  CAS  PubMed  Google Scholar 

  7. Erbguth FJ: From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008, 115: 559–565.

    Article  CAS  PubMed  Google Scholar 

  8. Kuo HC: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004, 63:868–872.

    Article  PubMed  Google Scholar 

  9. • Brubaker L, Richter HE, Visco A, et al.: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180:217–222. This randomized placebo controlled study was conducted to evaluate the efficacy of botulinum toxin A in OAB-wet patients.

    Article  PubMed  Google Scholar 

  10. • Cohen BL, Rivera R, Barboglio P, Gousse A: Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007, 177:1006–1010. This article discusses the safe use of flexible cystoscopy for injecting botulinum toxin A.

    Article  PubMed  Google Scholar 

  11. • Flynn MK, Amundsen CL, Perevich M, et al.: Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009, 181:2608–2615. This randomized controlled trial evaluated the use of botulinum toxin A.

    Article  CAS  PubMed  Google Scholar 

  12. Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231–2236.

    Article  CAS  PubMed  Google Scholar 

  13. • Khan S, Kessler TM, Apostolidis A, et al.: What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009, 181:1773–1778. This initial report details the effect of repeat injections of botulinum toxin A.

    Article  CAS  PubMed  Google Scholar 

  14. Schmid DM, Sauermann P, Werner M, et al.: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177–185.

    Article  CAS  PubMed  Google Scholar 

  15. Kuschel S, Werner M, Schmid DM, et al.: Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:905–909.

    Article  PubMed  Google Scholar 

  16. Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007, 178:1359–1363.

    Article  PubMed  Google Scholar 

  17. • Sahai A, Dowson C, Khan MS, et al.: Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010, 75:552–558. This is a report on dose optimization to improve voiding dysfunction after botulinum toxin A injection.

    Article  PubMed  Google Scholar 

  18. Chancellor MB: Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2009 July 2 (Epub ahead of print).

  19. Giannantoni A, Rossi A, Mearini E, et al.: Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol 2009, 182:1453–1457.

    Article  PubMed  Google Scholar 

  20. Sahai A, Dowson C, Khan MS, Dasgupta P: Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009, 103:1509–1515.

    Article  CAS  PubMed  Google Scholar 

  21. • Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009, 28:205–208. This initial report evaluates the optimal dose of botulinum toxin A for injection in patients with overactive bladder.

    Article  CAS  PubMed  Google Scholar 

  22. Jeffery S, Fynes M, Lee F, et al.: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007, 100:1302–1306.

    Article  CAS  PubMed  Google Scholar 

  23. Popat R, Apostolidis A, Kalsi V, et al.: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984–989.

    Article  CAS  PubMed  Google Scholar 

  24. Mohanty NK, Nayak RL, Alam M, Arora RP: Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience. Indian J Urol 2008, 24:182–185.

    Article  CAS  PubMed  Google Scholar 

  25. Khan S, Panicker J, Roosen A, et al.: Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks. Eur Urol 2009 April 21 (Epub ahead of print).

  26. Kalsi V, Apostolidis A, Popat R, et al.: Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006, 49:528–535.

    Article  PubMed  Google Scholar 

  27. Yablon SA, Brashear A, Gordon MF, et al.: Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007, 29:683–690.

    Article  CAS  PubMed  Google Scholar 

  28. Ashok K, Wang A: Detrusor overactivity: an overview. Arch Gynecol Obstet 2010, 282:33–41.

    Article  PubMed  Google Scholar 

  29. Digesu GA, Khullar V, Cardozo L, Salvatore S: Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003, 22:105–108. (Published erratum appears in Neurourol Urodyn 2003, 22:356.)

    Article  PubMed  Google Scholar 

  30. Dokmeci F, Seval M, Gok H: Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. Neurourol Urodyn 2010, 29:518–521.

    PubMed  Google Scholar 

  31. Gousse AE, Gomez CS, Kanagarajah P, et al.: Botox for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of urodynamically demonstrable detrusor overactivity. Neurourol Urodyn 2009, 28:107.

    Article  Google Scholar 

  32. Sahai A, Khan MS, Le Gall N, et al.: Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008, 71:455–459.

    Article  PubMed  Google Scholar 

  33. Kessler TM, Khan S, Panicker J, et al.: Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009, 113:1046–1051.

    PubMed  Google Scholar 

  34. De Laet K, Wyndaele JJ: Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005, 43:397–399.

    Article  PubMed  Google Scholar 

  35. Ruffion A, Capelle O, Paparel P, et al.: What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006, 97:1030–1034.

    Article  CAS  PubMed  Google Scholar 

  36. Adelson RT: Botulinum neurotoxins: fundamentals for the facial plastic surgeon. Am J Otolaryngol 2007, 28:260–266.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

No potential conflicts of interest relevant to this article have been reported.

Author information

Authors and Affiliations

  1. Department of Urology, University of Miami Miller School of Medicine, 1400 Northwest 10th Avenue, Suite 508, Miami, FL, 33136, USA

    Christopher S. Gomez, Prashanth Kanagarajah & Angelo Gousse

Authors
  1. Christopher S. Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prashanth Kanagarajah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelo Gousse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Gousse.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gomez, C.S., Kanagarajah, P. & Gousse, A. The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome. Curr Urol Rep 11, 353–359 (2010). https://doi.org/10.1007/s11934-010-0134-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-010-0134-4

Keywords

Search

Navigation